Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Has Consensus Price Target of $100.86

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given an average recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $100.86.

Several research firms have recently commented on TARS. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. The Goldman Sachs Group assumed coverage on Tarsus Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $116.00 price target on the stock. Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They set an “overweight” rating and a $110.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Elizabeth Lin sold 10,773 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $87.50, for a total value of $942,637.50. Following the sale, the insider directly owned 2,547 shares in the company, valued at approximately $222,862.50. This trade represents a 80.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $90.56, for a total value of $905,600.00. Following the sale, the chief executive officer owned 827,991 shares of the company’s stock, valued at approximately $74,982,864.96. This trade represents a 1.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 48,031 shares of company stock worth $4,004,227 over the last ninety days. 9.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of TARS. Hsbc Holdings PLC increased its holdings in Tarsus Pharmaceuticals by 295.0% in the 2nd quarter. Hsbc Holdings PLC now owns 38,090 shares of the company’s stock valued at $2,429,000 after buying an additional 28,447 shares during the period. Bank of New York Mellon Corp acquired a new stake in Tarsus Pharmaceuticals during the 2nd quarter valued at approximately $7,204,000. Bank of America Corp DE grew its holdings in shares of Tarsus Pharmaceuticals by 57.5% during the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock worth $83,786,000 after purchasing an additional 436,271 shares during the period. TimesSquare Capital Management LLC purchased a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $23,249,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $5,726,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $74.85 on Friday. Tarsus Pharmaceuticals has a 1-year low of $53.89 and a 1-year high of $91.53. The firm has a market capitalization of $3.69 billion, a price-to-earnings ratio of -68.67 and a beta of 0.34. The business’s 50-day moving average price is $75.16 and its two-hundred day moving average price is $67.89. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The firm had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. On average, equities analysts expect that Tarsus Pharmaceuticals will post -2.33 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.